Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 4186-4190

  Siu, Tony ^a   Liang, Jun ^a   Arruda, Jeannie ^a   Li, Yiwei ^a   Jones, Raymond E ^a   Defeo Jones, Deborah ^a   Barnett, Stanley F ^a   Robinson, Ronald G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Allosteric; Cell active; Kinase

Indexed keywords

PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR;

ALLOSTERISM; ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SOLVENTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47149104452     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.085     Document Type: Article

References (23)

1. Luo J., Manning B.D., and Cantley L.C. Cancer Cell 4 (2003) 257
2. Vivanco I., and Sawyers C.L. Nat. Rev. Cancer 2 (2002) 489
3. Hennessy B.T., Smith D.L., Ram R.T., Yiling L., and Milla G.B. Nat. Rev. Drug Discov. 4 (2005) 989
4. Cully M., You H., Levine A.J., and Mak T.W. Nat. Rev. Cancer 6 (2006) 184
5. Cantley L.C., and Neel B.G. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4240
6. Hsu J.H., Shi Y., Hu L.P., Fischer M., Franke T.F., and Lichenstein A. Oncogene 21 (2002) 1391
7. Page C., Lin H., Jin Y., Castle V.P., Nunez G., Huang M., and Lin H. J. Anticancer Res. 20 (2000) 407
8. Defeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvory E.M., Robinson R.G., Duggan M.E., Lindsley C.W., Zhao Z., Huber H.E., and Jones R.E. Mol. Cancer Ther. 4 (2005) 271
9. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Cancer Res. 61 (2001) 3986
10. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., and Duggan M.E. Bioorg. Med. Chem. Lett. 15 (2005) 761
11. Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., Duggan M.E., and Lindsley C.W. Bioorg. Med. Chem. Lett. 15 (2005) 905
12. Barnett S.F., Bilodeau M.T., and Lindsley C.W. Curr. Top. Med. Chem. 5 (2005) 109
13. Zhao Z., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huber H.E., Hartman G.D., Huber H.E., Duggan M.E., and Lindsley C.W. Bioorg. Med. Chem. Lett. 18 (2008) 49
14. Wu Z., Hartnett J.C., Neilson L., Robinson R.G., Fu S., Barnett S.F., Defeo-Jones D., Jones R.E., Kral A.M., Huber H., Hartman G.D., and Bilodeau M.T. Bioorg. Med. Chem. Lett. 18 (2008) 1274
15. Wu Z., Robinson R.G., Fu S., Barnett S.F., Defeo-Jones D., Jones R.E., Kral A.M., Huber H.E., Kohl N.E., Hartman G.D., and Bilodeau M.T. Bioorg. Med. Chem. Lett. 18 (2008) 2211
16. Hartnett J.C., Barnett S.F., Bilodeau M.T., Defeo-Jones D., Hartman G.D., Huber H.E., Jones R.E., Kral A.M., Robinson R.G., and Wu Z. Bioorg. Med. Chem. Lett. 18 (2008) 2194
17. Bilodeau M.T., Balitza A.E., Hoffman J.M., Manley P.J., Barnett S.F., Defeo-Jones D., Jones R.E., Robinson R.G., Smith A.M., Huber H.E., and Hartman G.D. Bioorg. Med. Chem. Lett. 18 (2008) 3178
18. 50 values. For Akt enzyme details, see:. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A., Leander K., Lee L.L., Malinowski J., McAvoy E.M., Nhas D.D., Robinson R., and Huber H.E. Biochem. J. 385 (2005) 399 For details on the Akt IPKA assay also see Ref. 3. Values are reported as single determinations ± standard deviations.
19. Chen P., Doweyko A.M., Norris D., Gu H.H., Spergel S.H., Das J., Moquin R.V., Lin J., Wityak J., Iwanowicz E.J., McIntyre K.W., Shuster D.J., Behnia K., Chong S., de Fex H., Pang S., Pitt S., Shen D.R., Thrall S., Stanley P., Kocy O.R., Witmer M.R., Kanner S.B., Schieven G.L., and Barrish J.C. J. Med. Chem. 47 (2004) 4517
20. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.H., and Denny W.A. J. Med. Chem. 40 (1997) 1519
21. Hennequin L.F., Stokes E.S., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
22. Bilodeau M.T., Rodman L.D., McGaughey G.B., Coll K.E., Koester T.J., Hoffman W.F., Hungate R.W., Kendall R.L., McFall R.C., Rickert K.W., Rutledge R.Z., and Thomas K.A. Bioorg. Med. Chem. Lett. 14 (2004) 2941
23. The introduction of the piperazine by displacement with the activating nitro-group was necessary because all efforts to displace the chloride of compound 39 failed.{A figure is presented}